Literature DB >> 10405373

Genetic basis for immunological aberrations in poliovirus Sabin serotype 3 strains imported in the netherlands.

J H Reimerink1, H G van der Avoort, A M van Loon, M P Koopmans.   

Abstract

During the characterization of poliovirus type 3 strains imported in The Netherlands, Sabin serotype 3 strains that reacted with both specific antisera against Sabin-like (vaccine) and non-Sabin-like (wild-type) strains by the intratypic strain differentiation assay have been found. The present study was done to determine the pathogenic potential of these virus strains for humans. Characterization of these so-called double-reactive strains with neutralizing monoclonal antibodies (MAbs) against the major antigenic sites of serotype 3 Sabin virus led to the identification of two groups with different antigenic properties. Six of the seven strains were resistant to neutralization with MAbs against sites 2B and 3B and one strain was neutralized by all the MAbs in a manner similar to that for the Sabin serotype 3 virus. Partial sequencing of the coding regions confirmed the antigenic changes for all six antigenically distinct strains. By inoculation of these viruses into transgenic mice which express the human poliovirus receptor, one strain was identified as highly neurovirulent, three were identified as intermediate, and three were identified as attenuated. Sera from vaccinated persons efficiently neutralized the mutants. Our data suggest that some double-reactive strains are a potential risk to the unvaccinated community but not to the vaccinated population.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10405373      PMCID: PMC85236     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

1.  Intratypic serodifferentiation of poliomyelitis virus strains by strain-specific antisera.

Authors:  A L van Wezel; A G Hazendonk
Journal:  Intervirology       Date:  1979       Impact factor: 1.763

2.  Antigenic structure of polioviruses of serotypes 1, 2 and 3.

Authors:  P D Minor; M Ferguson; D M Evans; J W Almond; J P Icenogle
Journal:  J Gen Virol       Date:  1986-07       Impact factor: 3.891

3.  Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3.

Authors:  P D Minor; D M Evans; M Ferguson; G C Schild; G Westrop; J W Almond
Journal:  J Gen Virol       Date:  1985-05       Impact factor: 3.891

4.  Studies on the attenuation of the Sabin type 3 oral polio vaccine.

Authors:  J W Almond; G D Westrop; D M Evans; G Dunn; P D Minor; D Magrath; G C Schild
Journal:  J Virol Methods       Date:  1987-08       Impact factor: 2.014

5.  Poliovirus-specific immunoglobulin A in persons vaccinated with inactivated poliovirus vaccine in The Netherlands.

Authors:  M M Herremans; A M van Loon; J H Reimerink; H C Rümke; H G van der Avoort; T G Kimman; M P Koopmans
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

6.  Complete nucleotide sequences of all three poliovirus serotype genomes. Implication for genetic relationship, gene function and antigenic determinants.

Authors:  H Toyoda; M Kohara; Y Kataoka; T Suganuma; T Omata; N Imura; A Nomoto
Journal:  J Mol Biol       Date:  1984-04-25       Impact factor: 5.469

7.  Nucleotide sequence from neurovirulent and attenuated strains of type 3 poliovirus.

Authors:  J W Almond; A J Cann; P D Minor; P Reeve; G C Schild; R Hauptmann; G Stanway
Journal:  Rev Infect Dis       Date:  1984 May-Jun

8.  Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world.

Authors:  A B Sabin
Journal:  J Infect Dis       Date:  1985-03       Impact factor: 5.226

9.  Monoclonal antibodies specific for the Sabin vaccine strain of poliovirus 3.

Authors:  M Ferguson; Q Yi-hua; P D Minor; D I Magrath; M Spitz; G C Schild
Journal:  Lancet       Date:  1982-07-17       Impact factor: 79.321

10.  Comparison of the complete nucleotide sequences of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon 12a1b.

Authors:  G Stanway; P J Hughes; R C Mountford; P Reeve; P D Minor; G C Schild; J W Almond
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

View more
  1 in total

1.  Isolation of an intertypic poliovirus capsid recombinant from a child with vaccine-associated paralytic poliomyelitis.

Authors:  Javier Martín; Elena Samoilovich; Glynis Dunn; Angie Lackenby; Esphir Feldman; Alan Heath; Ekaterina Svirchevskaya; Gill Cooper; Marina Yermalovich; Philip D Minor
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.